I asked both CLAUDE and CHAT GPT to scan recent lab industry investor calls for PAMA news and predictions. I include CLAUDE below; the two were similar. I include a cloud link to Chat GPT here.
This is direct AI output, offered as-is, I have not checked against original transcripts or audio files.
##
CLAUDE Opus
##
Please research public calls like investor calls for Carius, Tempus, Guardant, Natera, GenEDx, Neogenomics, Labcorp, and Quest, for evidence of specific remarks on PAMA pricing and how it might change their Medicare pricing and financial outlook. Use investor calls around August 1 (July 15-August 30) reflecting the quarter ending June 30, 2026. i am interested in specific quotes, for example, I understand that CARIS made a specific quote that its ASSURE test price would rise with the current PAMA cycle. Provide specific links and quotes.
##
PAMA on the Q2 2026 Earnings Calls:
What Eight Lab Companies Said About Medicare Pricing
The summer 2026 earnings season fell during the long-delayed PAMA private-payor data reporting cycle. The Consolidated Appropriations Act of 2026 postponed CLFS rate cuts until January 2027 and required laboratories to report first-half 2025 data during a mandatory window from May 1 to July 31, 2026. CMS will use that data to set CLFS rates for 2027–2029, with annual reductions for each test capped at 15%. No preliminary CY2027 rates appeared to be public as of mid-September.
This review covers calls for the quarter ending June 30, 2026, held between late July and early August, for Caris Life Sciences, Tempus AI, Guardant Health, Natera, GeneDx, NeoGenomics, Quest Diagnostics, and Labcorp. The companies split into three groups. Quest and Labcorp framed PAMA as a downside risk to be managed through legislation. Tempus and Guardant described Medicare price increases arriving through ADLT designation. Caris stood out as the one company projecting that the ordinary CDLT reset would raise its price. Natera and GeneDx did not address PAMA in the material reviewed.
Most full transcripts cited here are AI-generated and editor-reviewed by third-party services such as Investing.com and Benzinga. Speaker labels occasionally contain errors, and quotations should be verified against company webcast replays before further use.
Caris Life Sciences (August 5)
The most specific PAMA remark of the season came at the very end of Caris's Q&A. An analyst asked whether Caris Assure would gain more coverage as it approaches 200 million covered lives. CFO Luke Power said the company would keep pushing, noting that its code is now public on the clinical lab fee schedule, which is helping win contracts, with a strategy expected to play out into 2027. Chairman and CEO David Dean Halbert then added, per the Investing.com transcript: "We're expecting a price increase with PAMA." The sentence does not name Assure. It follows directly from the Assure discussion, but it can also be read as a company-wide statement (Investing.com transcript).
The CFO's prepared remarks were more measured. He reminded listeners that the clinical assays are billed as CDLTs and that Caris views its reimbursement position as "stable, with an expected update in September on the current PAMA reporting cycle" (StockAnalysis transcript).
The Q1 call in May supplies the background. Management explained that MI Cancer Seek was priced through crosswalk and Caris Assure through gapfill. Having not pursued ADLT status, both tests are subject to the three-year PAMA cycle. Caris submitted its data on May 1 and said it felt "very good about price stability" (Globe and Mail, Q1 transcript). Between May and August, the language moved from stability to an expected increase.
The PAMA mechanics explain why Caris would be optimistic. For a single-laboratory PLA code, the weighted median of private payor rates largely reflects that laboratory's own commercial payments. The 15% statutory limit applies only to reductions, not increases. A test initially priced by gapfill, whose commercial contracting expanded during 2025, is a plausible candidate for upward repricing.
Tempus AI (July 30)
Tempus did not discuss PAMA as such. Its Medicare pricing narrative centers on ADLT status. CEO Eric Lefkofsky said FDA approval of tumor-only xT CDx allows the company's entire solid tumor DNA portfolio to migrate under unified ADLT pricing, with an "estimated $200 uplift in ASP" worth roughly $85 million annually beginning in 2027. He added that once the xF liquid biopsy is approved, expected in the latter half of 2027, the incremental ASP lift would be a further $550, and that the two approvals together could add about $400 million of revenue in 2028.
On xF pricing, CFO Jim Rogers said the company now assumes a $7,500 ADLT price. Lefkofsky explained that the Tempus assay is comparable in size to Guardant's recently approved assay, making it difficult to enter the market at a much lower price. (Investing.com transcript)
Guardant Health (July 30)
Guardant's remarks also concerned ADLT rather than CDLT repricing. CFO Michael Bell was specific: "We're expecting a price of $8,455." He described this as an immediate uplift from the current $5,000 Medicare price for Guardant360, while noting that Medicare Advantage and commercial payers could take 12 to 24 months to align with the new rate, as happened after the earlier Guardant360 CDx ADLT. Co-CEO Helmy Eltoukhy said the company remains on track to obtain ADLT designation for Guardant360 Liquid CDx in the first half of 2027. (Motley Fool transcript)
For Shield, the relevant pricing statement came on the earlier Q1 call. Based on commercial and Medicare Advantage payments received in 2025, the $1,495 Medicare fee-for-service rate is established for 2026 and 2027 (Motley Fool, Q1 transcript).
Natera (August 6)
The full Natera transcript contains no reference to PAMA or the CLFS reset. The pricing discussion concerned Signatera ASP. CFO Mike Brophy said guidance assumes stable Signatera ASP of $1,275 through the balance of the year, with an upside case of roughly another $25. He estimated that pending and planned MolDX submissions could add something like $150 to $200 to ASP over the following 12 to 18 months. In organ health, management said the final Medicare transplant surveillance LCD, effective August 30, should improve Prospera ASP and volumes in the second half of the year (Investing.com transcript).
GeneDx (August 3)
No PAMA discussion surfaced in the GeneDx transcript excerpts and call summaries reviewed. The full transcript was not examined. The company's reimbursement commentary was directed at commercial payers. GeneDx reported a blended average reimbursement rate of $3,258 per test, roughly flat sequentially. The CFO described that level as the baseline for the rest of the year, with improvement targeted through product mix management, broader payer coverage, and stronger collection processes. (Yahoo Finance highlights)
NeoGenomics (July 28)
NeoGenomics addressed PAMA briefly, and dismissively, in response to an analyst question about prior authorization. CEO Tony Zook said the company continues to study the full range of policy initiatives, including PAMA and ACA changes, and works with ACLA. After assessing its portfolio, he said, it does not "see anything here that would be a significant impact" on the business in 2027. (Investing.com transcript)
Quest Diagnostics (July 23)
Quest offered the most detailed treatment of PAMA, which came up twice in Q&A. CEO Jim Davis outlined three possible outcomes. The first is that the current CMS data collection process leads to new rates effective January 1. Davis said the company has no idea how many of roughly 10,000 labs will report, noting that last time "only 1% of the labs submitted data."
The second outcome is passage of the RESULTS Act, which Davis said has more than 115 co-sponsors, about 60 endorsing patient and consumer organizations, and one successful House Energy and Commerce hearing, but still requires markup, CBO scoring, and a CMS technical assessment. Under that bill, rates would stay flat for 2027 and 2028, 2027 data would be collected, and new rates would take effect in 2029 with cuts capped at no more than 5% per year. The third outcome, if RESULTS does not pass this year, is another push for delay. Davis added that Quest would continue to advocate for RESULTS even if CMS implements new rates, and that he expects CMS to report on the data collection in late September or early October. (Benzinga transcript)
Labcorp (July 30)
Labcorp's call took place one day before the reporting deadline. CEO Adam Schechter noted that the submission deadline was the following day and said: "We've obviously submitted our data." He added that the company probably would not have significant insight into how many other laboratories submitted data until October. (Globe and Mail transcript)
According to a GuruFocus summary, Schechter described the RESULTS Act as having bipartisan support and progress, with another delay as the backup plan, and said the company would present a strong plan for next year at its Analyst Day in September. He also said hospitals are feeling pressure, which creates M&A opportunities for Labcorp. (Yahoo Finance/GuruFocus highlights)
Outlook
The calls show a clear division by business model. The national reference labs, whose revenue depends on high-volume routine tests, treat PAMA as a threat and are counting on the RESULTS Act or another delay. Oncology specialty labs mostly expect Medicare price increases through FDA approval and ADLT designation, which reprices annually on a separate track. Caris is the notable exception, projecting that the standard triennial CDLT reset will work in its favor.
Next steps include Labcorp's September Analyst Day and CMS's release of preliminary CY2027 CLFS rates, which both Caris and Quest pointed to for this fall.
